NewAmsterdam Pharma Company N.V. (NAMS) reported Q1 Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts NAMS Hot Sheet
Join SI Premium – FREE
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) reported Q1 Revenue for the quarter came in at $3.04 million versus the consensus estimate of $1.18 million.
For earnings history and earnings-related data on NewAmsterdam Pharma Company N.V. (NAMS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stevanato Group S.p.A. (STVN) Reports In-Line Q3 EPS
- Zebra Technologies (ZBRA) Tops Q3 EPS by 6c; offers guidance
- Archer Daniels Midland (ADM) Tops Q3 EPS by 20c; raises guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
